Patients with a germline TP53 mutation, or Li-Fraumeni Syndrome, have a 2.3–6.8% chance of lung cancer development [5], with the greatest frequency occurring in lung adenocarcinoma [6]. This evidence concerns the gene TP53 and lung cancer.